中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 8
Aug.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(8): 1748-1752

Diagnosis and treatment of hepatocellular carcinoma associated with nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2021.08.002

  • Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200029, China

  • Received Date: 2021-05-28
  • Accepted Date: 2021-05-28
  • Published Date: 2021-08-20
    Abstract
  • At present, the majority (> 80%) of hepatocellular carcinoma (HCC) cases in the world is mainly caused by chronic HBV or HCV infection, and in China, up to 80% of HCC cases are caused by HBV, but the mortality rate of HBV-related HCC has decreased by 30% recently. At the same time, obesity, type 2 diabetes, and nonalcoholic fatty liver disease (NAFLD) gradually replace hepatitis virus infection and alcohol abuse and have become the important pathogenic factors for HCC, and there is also a tendency of increase in HCC cases caused by metabolic dysfunction and fatty liver disease in recent years. For this reason, it is particularly important to investigate the diagnosis, treatment, and possible pathogenesis of HCC associated with NAFLD.

     

    • FullText(HTML)
  • loading
    • References(39)
  • [1]
    MARENGO A, ROSSO C, BUGIANESI E. Liver cancer: Connections with obesity, fatty liver, and cirrhosis[J]. Annu Rev Med, 2016, 67: 103-117. DOI: 10.1146/annurev-med-090514-013832.
    [2]
    PEISELER M, TACKE F. Inflammatory mechanisms underlying nonalcoholic steatohepatitis and the transition to hepatocellular carcinoma[J]. Cancers (Basel), 2021, 13(4): 730. DOI: 10.3390/cancers13040730.
    [3]
    MASSOUD O, CHARLTON M. Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis and hepatocellular carcinoma[J]. Clin Liver Dis, 2018, 22(1): 201-211. DOI: 10.1016/j.cld.2017.08.014.
    [4]
    YOUNOSSI ZM, GOLABI P, DE AVILA L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis[J]. J Hepatol, 2019, 71(4): 793-801. DOI: 10.1016/j.jhep.2019.06.021.
    [5]
    YOUNOSSI Z, STEPANOVA M, ONG JP, et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates[J]. Clin Gastroenterol Hepatol, 2019, 17(4): 748-755. e3. DOI: 10.1016/j.cgh.2018.05.057.
    [6]
    ESTES C, RAZAVI H, LOOMBA R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease[J]. Hepatology, 2018, 67(1): 123-133. DOI: 10.1002/hep.29466.
    [7]
    YOUNOSSI ZM, OTGONSUREN M, HENRY L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009[J]. Hepatology, 2015, 62(6): 1723-1730. DOI: 10.1002/hep.28123.
    [8]
    RINELLA M, CHARLTON M. The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health[J]. Hepatology, 2016, 64(1): 19-22. DOI: 10.1002/hep.28524.
    [9]
    ERTLE J, DECHÊNE A, SOWA JP, et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis[J]. Int J Cancer, 2011, 128(10): 2436-2443. DOI: 10.1002/ijc.25797.
    [10]
    DYSON J, JAQUES B, CHATTOPADYHAY D, et al. Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team[J]. J Hepatol, 2014, 60(1): 110-117. DOI: 10.1016/j.jhep.2013.08.011.
    [11]
    WALLACE MC, PREEN D, JEFFREY GP, et al. The evolving epidemiology of hepatocellular carcinoma: A global perspective[J]. Expert Rev Gastroenterol Hepatol, 2015, 9(6): 765-779. DOI: 10.1586/17474124.2015.1028363.
    [12]
    WANG FS, FAN JG, ZHANG Z, et al. The global burden of liver disease: The major impact of China[J]. Hepatology, 2014, 60(6): 2099-2108. DOI: 10.1002/hep.27406.
    [13]
    ZHOU M, WANG H, ZHU J, et al. Cause-specific mortality for 240 causes in China during 1990-2013: A systematic subnational analysis for the Global Burden of Disease Study 2013[J]. Lancet, 2016, 387(10015): 251-272. DOI: 10.1016/S0140-6736(15)00551-6.
    [14]
    CHO EJ, KWACK MS, JANG ES, et al. Relative etiological role of prior hepatitis B virus infection and nonalcoholic fatty liver disease in the development of non-B non-C hepatocellular carcinoma in a hepatitis B-endemic area[J]. Digestion, 2011, 84(Suppl 1): 17-22. DOI: 10.1159/000333210.
    [15]
    Bureau of Medical AdministrationNational Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.

    中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
    [16]
    MYERS S, NEYROUD-CASPAR I, SPAHR L, et al. NAFLD and MAFLD as emerging causes of HCC: A populational study[J]. JHEP Rep, 2021, 3(2): 100231. DOI: 10.1016/j.jhepr.2021.100231.
    [17]
    DUAN XY, QIAO L, FAN JG. Clinical features of nonalcoholic fatty liver disease-associated hepatocellular carcinoma[J]. Hepatobiliary Pancreat Dis Int, 2012, 11(1): 18-27. DOI: 10.1016/s1499-3872(11)60120-3.
    [18]
    STARLEY BQ, CALCAGNO CJ, HARRISON SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection[J]. Hepatology, 2010, 51(5): 1820-1832. DOI: 10.1002/hep.23594.
    [19]
    TOKUSHIGE K, HYOGO H, NAKAJIMA T, et al. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: Multicenter survey[J]. J Gastroenterol, 2016, 51(6): 586-596. DOI: 10.1007/s00535-015-1129-1.
    [20]
    KOBAYASHI S, MATSUI O, GABATA T, et al. Hemodynamics of small sclerosing hepatocellular carcinoma without fibrous capsule: Evaluation with single-level dynamic CT during hepatic arteriography[J]. Abdom Imaging, 2008, 33(4): 425-427. DOI: 10.1007/s00261-007-9288-z.
    [21]
    KANG BK, YU ES, LEE SS, et al. Hepatic fat quantification: A prospective comparison of magnetic resonance spectroscopy and analysis methods for chemical-shift gradient echo magnetic resonance imaging with histologic assessment as the reference standard[J]. Invest Radiol, 2012, 47(6): 368-375. DOI: 10.1097/RLI.0b013e31824baff3.
    [22]
    ZHANG ZJ, ZHENG ZJ, SHI R, et al. Metformin for liver cancer prevention in patients with type 2 diabetes: A systematic review and meta-analysis[J]. J Clin Endocrinol Metab, 2012, 97(7): 2347-53. DOI: 10.1210/jc.2012-1267.
    [23]
    TRAN KT, MCMENAMIN úC, COLEMAN HG, et al. Statin use and risk of liver cancer: Evidence from two population-based studies[J]. Int J Cancer, 2020, 146(5): 1250-1260. DOI: 10.1002/ijc.32426.
    [24]
    KOGISO T, TOKUSHIGE K. The current view of nonalcoholic fatty liver disease-related hepatocellular carcinoma[J]. Cancers (Basel), 2021, 13(3): 516. DOI: 10.3390/cancers13030516.
    [25]
    KUDO M, MATSUI O, IZUMI N, et al. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 Update by the Liver Cancer Study Group of Japan[J]. Liver Cancer, 2014, 3(3-4): 458-468. DOI: 10.1159/000343875.
    [26]
    BRUIX J, SHERMAN M. Management of hepatocellular carcinoma: An update[J]. Hepatology, 2011, 53(3): 1020-1022. DOI: 10.1002/hep.24199.
    [27]
    KOKUDO N, TAKEMURA N, HASEGAWA K, et al. Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update[J]. Hepatol Res, 2019, 49(10): 1109-1113. DOI: 10.1111/hepr.13411.
    [28]
    MALLIK R, CHOWDHURY TA. Metformin in cancer[J]. Diabetes Res Clin Pract, 2018, 143: 409-419. DOI: 10.1016/j.diabres.2018.05.023.
    [29]
    COYLE C, CAFFERTY FH, VALE C, et al. Metformin as an adjuvant treatment for cancer: A systematic review and meta-analysis[J]. Ann Oncol, 2016, 27(12): 2184-2195. DOI: 10.1093/annonc/mdw410.
    [30]
    SHI T, KOBARA H, OURA K, et al. Mechanisms underlying hepatocellular carcinoma progression in patients with type 2 diabetes[J]. J Hepatocell Carcinoma, 2021, 8: 45-55. DOI: 10.2147/JHC.S274933.
    [31]
    ADAM R, KARAM V, CAILLIEZ V, et al. 2018 Annual Report of the European Liver Transplant Registry (ELTR) - 50-year evolution of liver transplantation[J]. Transpl Int, 2018, 31(12): 1293-1317. DOI: 10.1111/tri.13358.
    [32]
    COTTER TG, CHARLTON M. Nonalcoholic steatohepatitis after liver transplantation[J]. Liver Transpl, 2020, 26(1): 141-159. DOI: 10.1002/lt.25657.
    [33]
    WONG RJ, CHEUNG R, AHMED A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U. S[J]. Hepatology, 2014, 59(6): 2188-2195. DOI: 10.1002/hep.26986.
    [34]
    CHARLTON MR, BURNS JM, PEDERSEN RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States[J]. Gastroenterology, 2011, 141(4): 1249-1253. DOI: 10.1053/j.gastro.2011.06.061.
    [35]
    YOUNOSSI Z, ANSTEE QM, MARIETTI M, et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(1): 11-20. DOI: 10.1038/nrgastro.2017.109.
    [36]
    HONAP S, OBEN JA. Fat and hidden liver cancer[J]. Clin Liver Dis (Hoboken), 2021, 17(2): 49-52. DOI: 10.1002/cld.1011.
    [37]
    RAMAI D, TAI W, RIVERA M, et al. Natural progression of non-alcoholic steatohepatitis to hepatocellular carcinoma[J]. Biomedicines, 2021, 9(2): 184. DOI: 10.3390/biomedicines9020184.
    [38]
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236. DOI: 10.1016/j.jhep.2018.03.019.
    [39]
    MARRERO JA, KULIK LM, SIRLIN CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 68(2): 723-750. DOI: 10.1002/hep.29913.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (848) PDF downloads(162) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return